Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Virginia
Memorial Sloan Kettering Cancer Center
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.
Bristol-Myers Squibb
Children's Oncology Group
Novartis
Celgene
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Novartis
National Cancer Institute (NCI)
Eli Lilly and Company